These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9846585)

  • 21. Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus.
    Reed DS; Lind CM; Lackemeyer MG; Sullivan LJ; Pratt WD; Parker MD
    Vaccine; 2005 May; 23(24):3139-47. PubMed ID: 15837213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attenuated Langat E5 virus as a live virus vaccine against Kyasanur Forest disease virus.
    Thind IS
    Indian J Med Res; 1981 Feb; 73():141-9. PubMed ID: 6263797
    [No Abstract]   [Full Text] [Related]  

  • 23. Detection of classical swine fever vaccine virus in blood and tissue samples of pigs vaccinated either with a conventional C-strain vaccine or a modified live marker vaccine.
    Koenig P; Hoffmann B; Depner KR; Reimann I; Teifke JP; Beer M
    Vet Microbiol; 2007 Mar; 120(3-4):343-51. PubMed ID: 17147979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal immunization with inactivated tick-borne encephalitis virus and the antigenic peptide 89-119 protects mice against intraperitoneal challenge.
    Goncharova E; Ryzhikov E; Poryvaev V; Bulychev L; Karpyshev N; Maksyutov A; Ryzhikov AB
    Int J Med Microbiol; 2006 May; 296 Suppl 40():195-201. PubMed ID: 16545605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in vaccination against tick-borne encephalitis.
    Rendi-Wagner P
    Expert Rev Vaccines; 2008 Jul; 7(5):589-96. PubMed ID: 18564014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys.
    Goletti D; Macchia I; Leone P; Pace M; Sernicola L; Pavone-Cossut MR; Maggiorella MT; Cafaro A; Ensoli B; Titti F
    Med Sci Monit; 2006 Oct; 12(10):BR330-40. PubMed ID: 17006396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of foreign protein epitopes at the surface of recombinant yellow fever 17D viruses based on three-dimensional modeling of its envelope protein.
    Bonaldo MC; Garratt RC; Freire MS; Galler R
    Cell Biochem Biophys; 2006; 44(3):313-24. PubMed ID: 16679518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spontaneous and engineered deletions in the 3' noncoding region of tick-borne encephalitis virus: construction of highly attenuated mutants of a flavivirus.
    Mandl CW; Holzmann H; Meixner T; Rauscher S; Stadler PF; Allison SL; Heinz FX
    J Virol; 1998 Mar; 72(3):2132-40. PubMed ID: 9499069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Innovative immunity.
    Beardsley T
    Sci Am; 1999 Feb; 280(2):42, 44. PubMed ID: 10049108
    [No Abstract]   [Full Text] [Related]  

  • 30. [Construction of infectious Japanese encephalitis virus clone based on the cDNA template of the attenuated live vaccine production strain SA14-14-2].
    Zeng M; Jia LL; Yu YX; Dong GM; Liu WX; Wang ZW; Li DF
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Mar; 19(1):9-11. PubMed ID: 16201461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetically engineered vaccines: an overview.
    Dertzbaugh MT
    Plasmid; 1998; 39(2):100-13. PubMed ID: 9514708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selection and analysis of mutations in an encephalomyocarditis virus internal ribosome entry site that improve the efficiency of a bicistronic flavivirus construct.
    Orlinger KK; Kofler RM; Heinz FX; Hoenninger VM; Mandl CW
    J Virol; 2007 Nov; 81(22):12619-29. PubMed ID: 17855533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus.
    Bonaldo MC; Garratt RC; Caufour PS; Freire MS; Rodrigues MM; Nussenzweig RS; Galler R
    J Mol Biol; 2002 Jan; 315(4):873-85. PubMed ID: 11812154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
    Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
    Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys.
    Monath TP; Myers GA; Beck RA; Knauber M; Scappaticci K; Pullano T; Archambault WT; Catalan J; Miller C; Zhang ZX; Shin S; Pugachev K; Draper K; Levenbook IS; Guirakhoo F
    Biologicals; 2005 Sep; 33(3):131-44. PubMed ID: 15975826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A synthetic peptide based on the NS1 non-structural protein of tick-borne encephalitis virus induces a protective immune response against fatal encephalitis in an experimental animal model.
    Volpina OM; Volkova TD; Koroev DO; Ivanov VT; Ozherelkov SV; Khoretonenko MV; Vorovitch MF; Stephenson JR; Timofeev AV
    Virus Res; 2005 Sep; 112(1-2):95-9. PubMed ID: 16022903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the effects of alterations in the tick-borne encephalitis virus 3'-noncoding region on translation and RNA replication using reporter replicons.
    Hoenninger VM; Rouha H; Orlinger KK; Miorin L; Marcello A; Kofler RM; Mandl CW
    Virology; 2008 Aug; 377(2):419-30. PubMed ID: 18533218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective efficacy of a recombinant plague vaccine when co-administered with another sub-unit or live attenuated vaccine.
    Griffin K; Bedford R; Townson K; Phillpotts R; Funnell S; Morton M; Williamson D; Titball R
    FEMS Immunol Med Microbiol; 2005 Mar; 43(3):425-30. PubMed ID: 15708318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Formulation, stability, and delivery of live attenuated vaccines for human use.
    Burke CJ; Hsu TA; Volkin DB
    Crit Rev Ther Drug Carrier Syst; 1999; 16(1):1-83. PubMed ID: 10099898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.